Acute Myeloid Leukemia (AML): Finally Making Progress?

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy that affects approximately 20,000 patients each year in the United States. Management of AML has changed little over the last several decades and outcomes remain unsatisfactory. However, recent drug discoveries and approvals show tremendous promise. This presentation will review the current treatment armamentarium of AML highlighting novel concepts and investigational agents in development.

Course summary
Available credit: 
  • 1.00 Participation

    UNC Lineberger Cancer Network certificate of participation.

    Tim Poe, Director of Telehealth

Course opens: 
08/10/2021
Course expires: 
12/31/2026
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 Participation

    UNC Lineberger Cancer Network certificate of participation.

    Tim Poe, Director of Telehealth

Price

Cost:
$0.00
Please login or register to take this course.